Dyne Therapeutics Advances Four DMD Candidates into IND-Enabling…

Event summary

Dyne Therapeutics will present preclinical data for four DMD candidates (DYNE-253, DYNE-245, DYNE-244, DYNE-255) at the 27th Annual NMSG Scientific Meeting on September 25-27, 2026.
All candidates leverage the FORCE™ platform, the same technology used in z-rostudirsen (DYNE-251), currently under FDA review for exon 51 DMD.
Data includes in vitro exon skipping results and in vivo pharmacokinetic/pharmacodynamic results for DYNE-253 in a Del52 mouse model.
Dyne aims to build a leading franchise across multiple DMD mutations, with all four candidates advancing into IND-enabling studies.

The big picture

Dyne Therapeutics is positioning itself as a leader in DMD treatment by expanding its pipeline beyond exon 51 skipping. The company's FORCE™ platform, if proven effective across multiple mutations, could significantly broaden its market reach. This strategy aligns with the broader industry trend of developing precision therapies for genetically driven neuromuscular diseases, where addressing a wider range of mutations can enhance patient access and commercial potential.

What we're watching

Platform Scalability: Whether Dyne can successfully replicate the FORCE™ platform's efficacy across multiple DMD mutations.
Regulatory Momentum: The pace at which z-rostudirsen (DYNE-251) progresses through FDA review and potential commercial launch.
Pipeline Expansion: How quickly Dyne can advance these four candidates into clinical trials and diversify its DMD portfolio.